H H Feldman

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi request reprint Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden
    Howard Feldman
    Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
    J Am Geriatr Soc 51:737-44. 2003
  2. pmc Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease
    Ian R Mackenzie
    Department of Pathology, University of British Columbia, Vancouver, BC, Canada
    BMC Neurol 6:32. 2006
  3. ncbi request reprint Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?
    Howard H Feldman
    Division of Neurology, University of British Columbia Hospital, Vancouver, BC, Canada
    Nat Clin Pract Neurol 5:128-9. 2009
  4. ncbi request reprint Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
    Howard H Feldman
    Division of Neurology, University of British Columbia Hospital, Vancouver, Canada
    Lancet Neurol 6:501-12. 2007
  5. ncbi request reprint Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment
    Howard H Feldman
    Division of Neurology, University of British Columbia, Vancouver, BC, Canada
    Alzheimer Dis Assoc Disord 20:263-8. 2006
  6. pmc Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
    Howard H Feldman
    Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
    J Neurol Neurosurg Psychiatry 78:1056-63. 2007
  7. doi request reprint Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
    H H Feldman
    Division of Neurology, University of British Columbia, UBCH Clinic for Alzheimer s Disease and Related Disorders, Vancouver, Canada
    Neurology 74:956-64. 2010
  8. pmc Diagnosis and treatment of dementia: 2. Diagnosis
    Howard H Feldman
    Division of Neurology, Department of Medicine, University of British Columbia, and the University of British Columbia Hospital Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC
    CMAJ 178:825-36. 2008
  9. doi request reprint Analyses of mortality risk in patients with dementia treated with galantamine
    H H Feldman
    University British Columbia Hospital, Vancouver, Canada
    Acta Neurol Scand 119:22-31. 2009
  10. doi request reprint Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease
    Howard H Feldman
    Division of Neurology, University British Columbia, Vancouver, British Columbia, Canada
    Int J Geriatr Psychiatry 24:479-88. 2009

Detail Information

Publications41

  1. ncbi request reprint Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden
    Howard Feldman
    Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
    J Am Geriatr Soc 51:737-44. 2003
    ....
  2. pmc Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease
    Ian R Mackenzie
    Department of Pathology, University of British Columbia, Vancouver, BC, Canada
    BMC Neurol 6:32. 2006
    ..The genetic basis of familial FTLD-U is currently not known, however the presence of NII suggests that a subset of cases may represent a polyglutamine expansion disease...
  3. ncbi request reprint Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?
    Howard H Feldman
    Division of Neurology, University of British Columbia Hospital, Vancouver, BC, Canada
    Nat Clin Pract Neurol 5:128-9. 2009
    ..We remind clinicians that small improvements in cognition matter most when a concurrent measurable benefit is seen in daily function...
  4. ncbi request reprint Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
    Howard H Feldman
    Division of Neurology, University of British Columbia Hospital, Vancouver, Canada
    Lancet Neurol 6:501-12. 2007
    ..To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline...
  5. ncbi request reprint Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment
    Howard H Feldman
    Division of Neurology, University of British Columbia, Vancouver, BC, Canada
    Alzheimer Dis Assoc Disord 20:263-8. 2006
    ..These post hoc analyses in moderate-to-severe AD patients receiving stable donepezil treatment suggest that memantine may impact overall functional levels, and some of the cognitive processing underlying ADL performance...
  6. pmc Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
    Howard H Feldman
    Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
    J Neurol Neurosurg Psychiatry 78:1056-63. 2007
    ..To evaluate the efficacy and safety of rapidly titrated rivastigmine administered twice (BID) or three times (TID) daily in patients with mild to moderate Alzheimer's disease (AD)...
  7. doi request reprint Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
    H H Feldman
    Division of Neurology, University of British Columbia, UBCH Clinic for Alzheimer s Disease and Related Disorders, Vancouver, Canada
    Neurology 74:956-64. 2010
    ..The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD...
  8. pmc Diagnosis and treatment of dementia: 2. Diagnosis
    Howard H Feldman
    Division of Neurology, Department of Medicine, University of British Columbia, and the University of British Columbia Hospital Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC
    CMAJ 178:825-36. 2008
    ..In this article, we provide physicians with practical guidance on the diagnosis of dementia based on recommendations from the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, held in March 2006...
  9. doi request reprint Analyses of mortality risk in patients with dementia treated with galantamine
    H H Feldman
    University British Columbia Hospital, Vancouver, Canada
    Acta Neurol Scand 119:22-31. 2009
    ..To analyze mortality data from patients with Alzheimer's disease (AD), Alzheimer's plus cerebrovascular disease (AD + CVD) or vascular dementia (VaD)...
  10. doi request reprint Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease
    Howard H Feldman
    Division of Neurology, University British Columbia, Vancouver, British Columbia, Canada
    Int J Geriatr Psychiatry 24:479-88. 2009
    ....
  11. ncbi request reprint Mild cognitive impairment
    Howard H Feldman
    Division of Neurology, Dept of Medicine, Clinic for Alzheimer Disease and Related Disorders, University of British Columbia, S192 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2B5
    Am J Geriatr Psychiatry 13:645-55. 2005
    ..The essentials of management include a thorough assessment directed at etiological determination and counseling and judicious use of available therapeutics...
  12. ncbi request reprint Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial
    Howard Feldman
    Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
    Int J Geriatr Psychiatry 20:559-69. 2005
    ..Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5-17)...
  13. ncbi request reprint Economic evaluation of donepezil in moderate to severe Alzheimer disease
    H Feldman
    Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
    Neurology 63:644-50. 2004
    ..To investigate the costs to society of Alzheimer disease (AD) care in a multinational, randomized, placebo-controlled trial of donepezil in patients with moderate to severe AD...
  14. ncbi request reprint Behavioral symptoms in mild cognitive impairment
    H Feldman
    Division of Neurology, University of British Columbia, Vancouver Hospital and Health Sciences Center, Vancouver, British Columbia, Canada
    Neurology 62:1199-201. 2004
    ..NPI+ subjects had significantly greater impairment on global, cognitive, and functional scores than NPI- subjects. The presence of neuropsychiatric symptoms appears to be a marker of MCI severity...
  15. ncbi request reprint A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results
    H Feldman
    Department of Medicine Neurology, Vancouver Hospital and Health Sciences Center, University of British Columbia, S192 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada
    Neuroepidemiology 22:265-74. 2003
    ..4%, dementia with Lewy bodies 2.5%, and unclassifiable 1.8%. The ACCORD cohort will allow a detailed study of the longitudinal course of CIND, and the longer-term outcomes of both treated and untreated dementia subjects...
  16. ncbi request reprint Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis
    Howard H Feldman
    Division of Neurology and Clinic for Alzheimer s Disease and Related Disorders, University of British Columbia, Vancouver, BC, Canada
    Alzheimer Dis Assoc Disord 19:29-36. 2005
    ..Small changes in ADAS-cog are nevertheless associated with a substantial measurable effect on the daily lives of both patients and caregivers...
  17. ncbi request reprint A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
    H Feldman
    Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
    Neurology 57:613-20. 2001
    ..To investigate the efficacy and safety of donepezil in patients with moderate to severe AD (standardized Mini-Mental State Examination [sMMSE] scores of 5 to 17; Functional Assessment Staging score < or =6 at baseline)...
  18. ncbi request reprint Neuropsychological subgroups of cognitively-impaired-not-demented (CIND) individuals: delineation, reliability, and predictive validity
    Kevin R Peters
    Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Exp Neuropsychol 27:164-88. 2005
    ..The Verbal Dysfunction subgroup was most likely to show improvement in cognitive status. The cognitive heterogeneity of the CIND condition must be taken into account in future research focusing on the early identification of dementia...
  19. ncbi request reprint Neuropsychological characterization of cognitively-impaired-not-demented (CIND) individuals: clinical comparison data
    Kevin R Peters
    University of British Columbia, Vancouver, BC, Canada
    Clin Neuropsychol 18:208-28. 2004
    ..The results support the impression that CIND is a cognitively heterogeneous condition...
  20. pmc Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging
    Ging Yuek R Hsiung
    Department of Medicine, Clinic for Alzheimer s Disease and Related Disorders, University of British Columbia, Vancouver, BC
    CMAJ 171:863-7. 2004
    ..However, its effect on predicting conversion from normal to "cognitive impairment, no dementia" (CIND) and from CIND to AD is less clear...
  21. ncbi request reprint Extrapyramidal features in patients with motor neuron disease and dementia; a clinicopathological correlative study
    Ian R Mackenzie
    Department of Pathology, Vancouver General Hospital and University of British Columbia, 855 West 12th Avenue, V5Z 1M9, Vancouver, British Columbia, Canada
    Acta Neuropathol 107:336-40. 2004
    ..This study illustrates the utility of ubiquitin immunohistochemistry in demonstrating the range of pathology in MND and provides a neuropathological correlate for the extrapyramidal features which may occur in MND with dementia...
  22. ncbi request reprint Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
    Hao Li
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Arch Neurol 65:45-53. 2008
    ..To identify single-nucleotide polymorphisms (SNPs) associated with risk and age at onset of Alzheimer disease (AD) in a genomewide association study of 469 438 SNPs...
  23. doi request reprint Clinical presentation of prodromal frontotemporal dementia
    Bradley J Hallam
    Division of Neurology, Geriatric Psychiatry Outreach Team, Vancouver Hospital, Vancouver, British Columbia
    Am J Alzheimers Dis Other Demen 22:456-67. 2007
    ....
  24. doi request reprint Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease
    Roger Lane
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Pharmacogenet Genomics 18:289-98. 2008
    ..To evaluate the synergistic effects of the apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI)...
  25. ncbi request reprint Assessing mental status in dementia: the behavioral neurology assessment--right time? Right place?
    Howard H Feldman
    Can J Neurol Sci 32:138-9. 2005
  26. doi request reprint Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort
    Ging Yuek R Hsiung
    Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Dement Geriatr Cogn Disord 25:483-90. 2008
    ..We evaluated whether impairments on the Disability Assessment for Dementia (DAD) and Functional Rating Scale (FRS) can predict progression to AD...
  27. ncbi request reprint Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals
    Kevin R Peters
    Department of Psychology, Trent University, Peterborough, Ontario, Canada
    Am J Geriatr Psychiatry 16:136-44. 2008
    ....
  28. ncbi request reprint Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria
    Bruno Dubois
    INSERM U610, Hopital de la Salpetriere, Paris, France
    Lancet Neurol 6:734-46. 2007
    ..Validation studies in existing and prospective cohorts are needed to advance these criteria and optimise their sensitivity, specificity, and accuracy...
  29. ncbi request reprint Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias
    Ging Yuek R Hsiung
    Division of Neurology, Department of Medicine University of British Columbia, Vancouver, Canada
    Dement Geriatr Cogn Disord 22:413-20. 2006
    ..People who are cognitively impaired not demented (CIND) can be at an increased risk for developing dementia, but little is known about the natural history of CIND in clinical settings...
  30. doi request reprint Cognitive impairment no dementia - neuropsychological and neuroimaging characterization of an amnestic subgroup
    Claudia Jacova
    Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Dement Geriatr Cogn Disord 25:238-47. 2008
    ..In this study a prospectively defined amnestic CIND group was characterized on a detailed neuropsychological test battery and on structural magnetic resonance imaging (MRI) measures...
  31. ncbi request reprint Dropouts and refusals in observational studies: lessons for prevention trials
    Claudia Jacova
    Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Neurology 67:S17-20. 2006
    ..Targeted strategies to retain these individuals within prevention studies will be needed to achieve sufficient study power and validity...
  32. ncbi request reprint Primary prevention and delay of onset of AD/dementia
    Howard H Feldman
    Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Can J Neurol Sci 34:S84-9. 2007
    ..It is foreseeable that regulatory authorities will be presented with primary prevention RCTs for approval and labelling, and that criteria to evaluate such evidence still need to be developed...
  33. ncbi request reprint Is mild cognitive impairment a valid target of therapy
    Kenneth Rockwood
    Department of Medicine Geriatric Medicine and Neurology, Dalhousie University, Halifax, NS, Canada
    Can J Neurol Sci 34:S90-6. 2007
    ..The phenomenon of slowing or non-progression itself should be investigated, and such investigations likely should extend to people now classified as having mild dementia...
  34. ncbi request reprint Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary
    Howard H Feldman
    Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
    Can J Neurol Sci 33:6-26. 2006
    ..They are intended to provide a common point of reference and guidance in Canada for therapeutic development of the dementias...
  35. ncbi request reprint Clinical phenotypes of Cerebral Amyloid Angiopathy
    Luis F Maia
    Department of Neurology, Hospital Geral Santo Antonio, Porto, Portugal
    J Neurol Sci 257:23-30. 2007
    ..Dementia, cognitive impairment and transient neurological symptoms or signs are also being increasingly recognized as part of the CAA clinical spectrum. This review covers the clinical, pathological and neuroimaging aspects of CAA...
  36. ncbi request reprint Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum
    Ian R A Mackenzie
    Division of Neuropathology, University of British Columbia, Vancouver, Canada
    J Neuropathol Exp Neurol 64:730-9. 2005
    ..The only finding restricted to a specific subgroup of patients was the presence of ub-ir neuronal intranuclear inclusions in some cases of familial FTD...
  37. ncbi request reprint Cholesterol in Alzheimer's disease
    Leila A Shobab
    Division of Neurology, Department of Medicine, Clinic for Alzheimer Disease and Related Disorders, Vancouver Costal Health, University of British Columbia, Vancouver BC, V6T 2B5, Canada
    Lancet Neurol 4:841-52. 2005
    ..In this review, we summarise current knowledge of the role of cholesterol metabolism in the pathogenesis of AD and examine the potential of statins in the prevention and treatment of AD...
  38. doi request reprint Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease
    Howard H Feldman
    Stroke 39:2894-7. 2008
    ..In cerebral amyloid angiopathy (CAA), there is amyloid deposition in meningeal and meningo-cortical arteries and capillaries, predisposing them to rupture. CAA is frequently associated with Alzheimer disease (AD)...
  39. ncbi request reprint Early identification of Alzheimer's disease: what have we learned from mild cognitive impairment?
    Howard H Feldman
    CNS Spectr 13:4-7. 2008
  40. ncbi request reprint The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene
    Ian R A Mackenzie
    Department of Pathology and Laboratory Medicine, University of British Columbia and Vancouver Coastal Health Vancouver, BC, Canada
    Brain 129:3081-90. 2006
    ..These findings suggest that FTD caused by PGRN mutations has a recognizable pathology with the most characteristic feature being ub-ir NII...
  41. doi request reprint Potential for misclassification of mild cognitive impairment: a study of memory scores on the Wechsler Memory Scale-III in healthy older adults
    Brian L Brooks
    British Columbia Mental Health and Addiction Services, Riverview Hospital, Coquitlam, British Columbia
    J Int Neuropsychol Soc 14:463-78. 2008
    ..Understanding the base rates of low scores can reduce the overinterpretation of low memory scores and minimize false-positive misclassification...